ABCD 2010

1 Treatments

Studied treatment  intracoronary stem cell implantation (Autologous Bone Marrow Cells)

Control treatment

Concomittant treatments  -

cell type  -

Cell injection procedure  -

2 Patients

Patients  Patients with nonischemic dilated cardiomyopathy

Inclusion criteria  having dilated cardiomyopathy with an ejection fraction (EF) of 35%, were New York Heart Association (NYHA) functional class II or more symptomatic for more than 6 months, had normal coronary arteries, and had no other comorbidities such as chronic renal or liver failure or any malignancy

Exclusion criteria  -

3 Methods

Blinding  -

Design  -

Centers  -

Geographical area  -

Sizes  24/20

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>acute heart failure</td>
<td>-/24</td>
<td>-/20</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>ventricular tachycardia</td>
<td>-/24</td>
<td>-/20</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>NYHA deterioration</td>
<td>-/24</td>
<td>-/20</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>cardiac event</td>
<td>-/24</td>
<td>-/20</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all-cause mortality</td>
<td>-/24</td>
<td>-/20</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References